Cargando…

Management of Cancer-Associated Myositis

PURPOSE OF THE REVIEW: Cancer-associated myositis (CAM) is defined as when cancer appears within 3 years of myositis onset. Dermatomyositis and seronegative immune–mediated necrotizing myopathy are the phenotypes mostly related to cancer. In general, treatment principles in myositis patients with an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Selva-O’Callaghan, Albert, Trallero-Araguás, Ernesto, Ros, Javier, Gil-Vila, Albert, Lostes, Julia, Agustí, Antonia, Riera-Arnau, Judit, Alvarado-Cárdenas, Marcelo, Pinal-Fernandez, Iago
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Other CTD: Inflammatory Myopathies and Sjogren's (I Pinal-Fernández, Section Editor)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9589595/ https://www.ncbi.nlm.nih.gov/pubmed/36313478 http://dx.doi.org/10.1007/s40674-022-00197-2

Ejemplares similares

Pharmacologic Treatment of Anti-MDA5 Rapidly Progressive Interstitial Lung Disease
por: Selva-O’Callaghan, A., et al.
Publicado: (2021)

Exercise in Myositis
por: Alexanderson, Helene
Publicado: (2018)

Current Treatment for Myositis
por: Barsotti, Simone, et al.
Publicado: (2018)

Development of the prediction model for hypertension in patients with idiopathic inflammatory myopathies
por: Qin, Li, et al.
Publicado: (2021)

Idiopathic inflammatory myopathies and hypertension: Possible involvement of hormonal factors
por: Armanini, Decio, et al.
Publicado: (2021)

Novel myosin-based therapies for congenital cardiac and skeletal myopathies
por: Ochala, Julien, et al.
Publicado: (2016)

Factors Associated With Treatment Response in Patients With Idiopathic Inflammatory Myopathies: A Registry‐Based Study
por: Espinosa‐Ortega, Fabricio, et al.
Publicado: (2022)

Coordinated local RNA overexpression of complement induced by interferon gamma in myositis
por: Casal-Dominguez, Maria, et al.
Publicado: (2023)

Anti-MDA5 Antibodies in a Large Mediterranean Population of Adults with Dermatomyositis
por: Labrador-Horrillo, Moises, et al.
Publicado: (2014)

Update in juvenile myositis
por: Nistala, Kiran, et al.
Publicado: (2013)

Update in inclusion body myositis
por: Machado, Pedro, et al.
Publicado: (2013)

Genetics in inclusion body myositis
por: Rothwell, Simon, et al.
Publicado: (2017)

SIGLEC1 is a biomarker of disease activity and indicates extraglandular manifestation in primary Sjögren's syndrome
por: Rose, Thomas, et al.
Publicado: (2016)

Familial Risk of Sjögren's Syndrome and Co‐aggregation of Autoimmune Diseases in Affected Families: A Nationwide Population Study
por: Kuo, Chang‐Fu, et al.
Publicado: (2015)

Epigenetic Signatures of Salivary Gland Inflammation in Sjögren's Syndrome
por: Cole, Michael B., et al.
Publicado: (2016)

Subjective and Objective Measures of Dryness Symptoms in Primary Sjögren's Syndrome: Capturing the Discrepancy
por: Bezzina, Oriana M., et al.
Publicado: (2017)

Mixed‐Methods Study Identifying Key Intervention Targets to Improve Participation in Daily Living Activities in Primary Sjögren's Syndrome Patients
por: Hackett, Katie L., et al.
Publicado: (2018)

Health-related quality of life and depression among participants in the Sjögren’s International Collaborative Clinical Alliance registry
por: Chou, Annie, et al.
Publicado: (2017)

Patient burden of Sjögren’s: a comprehensive literature review revealing the range and heterogeneity of measures used in assessments of severity
por: Hammitt, Katherine M, et al.
Publicado: (2017)

Hospitalisation rates among patients with primary Sjögren’s syndrome: a population-based study, 1995–2016
por: Maciel, Gabriel, et al.
Publicado: (2018)

Phosphatidylinositol 3-kinase delta pathway: a novel therapeutic target for Sjögren’s syndrome
por: Nayar, Saba, et al.
Publicado: (2019)

Increased mTORC1 activation in salivary gland B cells and T cells from patients with Sjögren’s syndrome: mTOR inhibition as a novel therapeutic strategy to halt immunopathology?
por: Blokland, Sofie L M, et al.
Publicado: (2019)

Salivary gland secretome: a novel tool towards molecular stratification of patients with primary Sjögren’s syndrome and non-autoimmune sicca
por: Blokland, Sofie L M, et al.
Publicado: (2019)

Salivary Gland Stem Cells Age Prematurely in Primary Sjögren's Syndrome
por: Pringle, Sarah, et al.
Publicado: (2018)

Sjögren’s syndrome: state of the art on clinical practice guidelines
por: Romão, Vasco C, et al.
Publicado: (2018)

Salivary gland ultrasound abnormalities in primary Sjögren’s syndrome: consensual US-SG core items definition and reliability
por: Jousse-Joulin, Sandrine, et al.
Publicado: (2017)

Pain and depression are associated with both physical and mental fatigue independently of comorbidities and medications in primary Sjögren’s syndrome
por: Hackett, Kate L, et al.
Publicado: (2019)

Cigarette smoking patterns preceding primary Sjögren’s syndrome
por: Mofors, Johannes, et al.
Publicado: (2020)

Salivary Gland Mucosa‐Associated Lymphoid Tissue–Type Lymphoma From Sjögren’s Syndrome Patients in the Majority Express Rheumatoid Factors Affinity‐Selected for IgG
por: Bende, Richard J., et al.
Publicado: (2020)

Autoantigen TRIM21/Ro52 is expressed on the surface of antigen-presenting cells and its enhanced expression in Sjögren’s syndrome is associated with B cell hyperactivity and type I interferon activity
por: Hillen, Maarten R, et al.
Publicado: (2020)

Unique expansion of IL-21+ Tfh and Tph cells under control of ICOS identifies Sjögren’s syndrome with ectopic germinal centres and MALT lymphoma
por: Pontarini, Elena, et al.
Publicado: (2020)

Antigen-driven selection of antibodies against SSA, SSB and the centromere ‘complex’, including a novel antigen, MIS12 complex, in human salivary glands
por: Takeshita, Masaru, et al.
Publicado: (2020)

Type I IFN system activation in newborns exposed to Ro/SSA and La/SSB autoantibodies in utero
por: Hedlund, Malin, et al.
Publicado: (2020)

Protein and DNA methylation-based scores as surrogate markers for interferon system activation in patients with primary Sjögren’s syndrome
por: Björk, Albin, et al.
Publicado: (2020)

Large granular lymphocyte expansions in primary Sjögren’s syndrome: characteristics and outcomes
por: Baber, Alistair, et al.
Publicado: (2019)

Anti-RNP positivity in primary Sjögren’s syndrome is associated with a more active disease and a more frequent muscular and pulmonary involvement
por: Abbara, Salam, et al.
Publicado: (2019)

Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjögren’s syndrome
por: Brito-Zerón, Pilar, et al.
Publicado: (2019)

Incorporation of Salivary Gland Ultrasonography Into the American College of Rheumatology/European League Against Rheumatism Criteria for Primary Sjögren's Syndrome
por: van Nimwegen, Jolien F., et al.
Publicado: (2020)

Improvement of Severe Fatigue Following Nuclease Therapy in Patients With Primary Sjögren’s Syndrome: A Randomized Clinical Trial
por: Posada, James, et al.
Publicado: (2020)

Efficacy and safety of abatacept in active primary Sjögren’s syndrome: results of a phase III, randomised, placebo-controlled trial
por: Baer, Alan N, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_s3e9j5i4av2aclquja3pq3s3mh